Increased cholesterol efflux potential of sera from ApoA-I(Milano) carriers and transgenic mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 5, 1999, Pages 1257-1262

  Franceschini, Guido ^a   Calabresi, Laura ^b   Chiesa, Giulia ^b   Parolini, Cinzia ^b   Sirtori, Cesare R ^b   Canavesi, Monica ^b   Bernini, Franco ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b NONE

Author keywords

ApoA I; Cholesterol efflux; HDL; Reverse cholesterol transport; Transgenic mice

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HUMAN; LIVER METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSGENIC MOUSE;

EID: 0032935775     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.5.1257     Document Type: Article

References (37)

1. Gordon DJ, Rifkind BM. High density lipoprotein: the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1316.
2. Badimon JJ, Fuster V, Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. Circulation 1992;86:III-86-III-94.
3. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-162.
4. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211-228.
5. Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res. 1996;37:2473-2491.
6. Rodrigueza WV, Williams KJ, Rothblat GH, Phillips MC. Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol. Arterioscler Thromb Vasc Biol. 1997;17:383-393.
7. Franceschini G, Werba JP, Calabresi L. Drug control of reverse cholesterol transport. Pharmacol Ther. 1994;61:289-324.
8. de la Llera Moya M, Atger V, Paul JL, Fournier N, Moatti N, Giral P, Friday KE, Rothblat GH. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb. 1994;14:1056-1065.
9. Syvanne M, Castro G, Dengremont C, De Geitere C, Jauhiainen M, Ehnholm C, Michelagnoli S, Franceschini G, Kahri J, Taskinen MR. Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: importance of LpA-I:A-II particles and phospholipid transfer protein. Atherosclerosis. 1996;127:245-253.
10. Elkhalil L, Majd Z, Bakir R, Perez-Mendez O, Castro G, Poulain P, Lacroix B, Duhal N, Fruchart JC, Luc G. Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. Metabolism. 1997;46:474-483.
11. Alger V, de la Llera Moya M, Bamberger M, Francone O, Cosgrove P, Tall AR, Walsh A, Moatti N, Rothblat G. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI. J Clin Invest. 1995;96:2613-2622.
12. Castro G, Nihoul LP, Dengremont C, De Geitere C, Delfly B, Tailleux A, Fievet C, Duverger N, Denefle P, Fruchart JC, Rubin EM. Cholesterol efflux, lecithin-cholesterol acyltransferase activity, and pre-beta particle formation by serum from human apolipoprotein A-I and apolipoprotein A-I/ apolipoprotein A-II transgenic mice consistent with the latter being less effective for reverse cholesterol transport. Biochemistry. 1997;36:2243-2249.
13. Milano apoprotein: decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest. 1980;66:892-900.
14. Milano apoprotein: identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet. 1985;37:1083-1097.
15. Franceschini G, Sirtori CR, Bosisio E, Gualandri V, Orsini GB, Mogavero AM, Capurso A. Relationship of the phenotypic expression of the A-I Milano apoprotein with plasma lipid and lipoprotein patterns. Atherosclerosis. 1985;58:159-174.
16. Milano: partial lecithin:cholesterol acyltransferase deficiency due to low levels of a functional enzyme. Biochim Biophys Acta. 1990; 1043:1-6.
17. Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles. J Lipid Res. 1993;34:111-123.
18. Milano. Atherosclerosis. 1998;136:139-146.
19. Milano transgenic mice. J Lipid Res. 1997; 38:2314-2321.
20. Franceschini G, Tosi C, Moreno Y, Sirtori CR. Effects of storage on the distribution of high density lipoprotein subfractions in human sera. J Lipid Res. 1985;26:1368-1373.
21. Li H, Reddick RL, Maeda N. Lack of apoA-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb. 1993;13:1814-1821.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol. Chem. 1951;193:265-275.
23. Warnick GR, Benderson J, Albers JJ. Dextran sulfate precipitation procedure for quantitation of high density lipoproteins. Clin Chem. 1982;28: 1379-1388.
24. Schultz JR, Gong EL, McCall MR, Nichols AV, Clift SM, Rubin EM. Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J Biol Chem. 1992;267:21630-21636.
25. Rifai N, King ME. Immunoturbidimetric assays of apolipoproteins A, AI, AII and B in serum. Clin Chem. 1986;32:957-961.
26. Weisgraber KH, Bersot TP, Mahley RW, Franceschini G, Sirtori CR. A-I Milano apoprotein: isolation and characterization of a cysteine-containmg variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest. 1980;66:901-907.
27. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1354.
28. Milano: correlation between lipoprotein subclass distribution and triglyceridemia. Arteriosclerosis. 1987;7:426-435.
29. Fournier N, de la Llera Moya M, Burkey BF, Swaney JB, Paterniti JR Jr, Moatti N, Atger V, Rothblat GH. Role of HDL phospholipid in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats. J Lipid Res. 1996;37:1704-1711.
30. Jian B, de la Llera-Moya M, Royer L, Rothblat G, Francone O, Swaney JB. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J Lipid Res. 1997;38:734-744.
31. Chiesa G, Parolini C, Canavesi M, Sirtori CR, Fumagalli R, Franceschini G, Bernini F. Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice. Arterioscler Thromb Vasc Biol. 1998;18:1417-1423.
32. Ji Y, Jian B, Wane N, Sun Y, Moya ML, Phillips MC, Rothblat GH, Swaney JB, Tall AR. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem. 1997;272: 20982-20985.
33. Jian B, de la Llera-Moya M, Ji Y, Wang N, Phillips MC, Swaney JB, Tall AR, Rothblat GH. Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. J Biol Chem. 1998;273:5599-5606.
34. Milano variant. J Biol Chem. 1982;257:9926-9930.
35. Calabresi L, Vecchio G, Frigerio F, Vavassori L, Sirtori CR, Franceschini G. Reconstituted high-density lipoproteins with a disulfide-linked apolipoprotein A-I dimer: evidence for restricted particle size heterogeneity. Biochemistry. 1997;36:12428-12433.
36. Milano mutation. In: Jacotot B, Mathé D, Fruchart JC, eds. Atherosclerosis XI. Singapore: Elsevier Science Pte Ltd; 1998: 1129-1134.
37. Stein O, Dabach Y, Hollander G, Ben-Naim M, Halperin G, Breslow JL, Stein Y. Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice. Proc Natl Acad Sci U S A. 1997;94: 9820-9824.